Nexalin Technology (NXL) Notes Payables (2021 - 2023)
Nexalin Technology's quarterly Notes Payables came in at $500000.0 in Q3 2023, little changed year-on-year from $500000.0 in Q3 2022, and little changed quarter-over-quarter from $500000.0 in Q2 2023.
Nexalin Technology has reported Notes Payables for 3 years, with the latest figure at $500000.0 in Q3 2023.
- For the quarter ending Q3 2023, Notes Payables changed 0.0% year-over-year to $500000.0; the trailing twelve-month figure through Sep 2023 stood at $500000.0 (changed 0.0% YoY), and the FY2022 full-year result was $500000.0, changed 0.0% from the prior year.
- Notes Payables for Q3 2023 stood at $500000.0, roughly flat from $500000.0 in the prior quarter.
- The five-year high for Notes Payables was $500000.0 in Q4 2021, with the low at $500000.0 in Q4 2021.
- Average Notes Payables over 3 years is $500000.0, with a median of $500000.0 recorded in 2021.
- Peak annual rise in Notes Payables reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
- Tracing NXL's Notes Payables over 3 years: stood at $500000.0 in 2021, then changed by 0.0% to $500000.0 in 2022, then changed by 0.0% to $500000.0 in 2023.
- The last three Notes Payables figures came in at $500000.0 (Q3 2023), $500000.0 (Q2 2023), and $500000.0 (Q1 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 500,000.00 |
| Jun 30, 2023 | 500,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 500,000.00 |
| Sep 30, 2022 | 500,000.00 |
| Dec 31, 2021 | 500,000.00 |